IDRI joins ADITEC to accelerate human vaccine development
Tuesday, October 18, 2011
The Infectious Disease Research Institute (IDRI) has joined the Advanced Immunization Technologies (ADITEC) program, a collaborative initiative dedicated to accelerating the development of the next generation of human vaccines. Launched on October 1st, ADITEC will operate with 30 million euros in funding over the course of 5 years contributed by the European Union, with an additional 11 million euros in funding from collaborating organizations.
ADITEC’s team comprises 42 universities and research institutions spanning13 countries, including competitive European establishments and leading vaccine development, systems biology, and adjuvant centers in the U.S. The project is reinforced by a number of key European industries, including both large pharmaceutical and smaller biotechnology companies. These corporations are focusing on specific innovative technologies that will enable the development and manufacturing of safer vaccines. Additionally, the World Health Organization is supporting the project as a senior partner, ensuring that cross-cutting global health aspects of vaccines are appropriately considered.
This partnership covers a wide range of crucial aspects of vaccination, from basic research and new technologies to clinical trials and public health. It is anticipated that this high-impact project will lead to improved potency and safety of vaccines and their components; novel routes and devices of administration; optimized vaccination strategies; optimized formulations and vaccination methods for different age groups; better insight on the effects of gender; chronic diseases and genetic variation on vaccination; and widespread knowledge about the available new technologies.